1. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial. (June 2022) Authors: Nanchahal, Jagdeep; Ball, Catherine; Rombach, Ines; Williams, Lynn; Kenealy, Nicola; Dakin, Helen; O'Connor, Heather; Davidson, Dominique; Werker, Paul; Dutton, Susan J; Feldmann, Marc; Lamb, Sarah E Journal: Lancet Issue: Volume 4:Number 6(2022) Page Start: e407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗